Compare LODE & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | HUMA |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 165.7M |
| IPO Year | 2004 | 2020 |
| Metric | LODE | HUMA |
|---|---|---|
| Price | $1.76 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 1.5M | ★ 5.6M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.55 | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $2,038,000.00 |
| Revenue This Year | $303.79 | $72.32 |
| Revenue Next Year | $410.04 | $518.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.76 | $0.34 |
| 52 Week High | $4.98 | $1.90 |
| Indicator | LODE | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 17.98 | 39.73 |
| Support Level | N/A | N/A |
| Resistance Level | $3.32 | $0.75 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 3.48 | 47.46 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.